{"id":"abbv-552","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4297572","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking S1PR1, ABBV-552 aims to reduce inflammation and modulate immune responses. This mechanism is being explored for its potential in treating autoimmune diseases.","oneSentence":"ABBV-552 is a small molecule inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:16.215Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT05771428","phase":"PHASE2","title":"Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-06-05","conditions":"Alzheimer's Disease (AD)","enrollment":263},{"nctId":"NCT06278766","phase":"PHASE1","title":"A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-02-21","conditions":"Healthy Volunteer","enrollment":8},{"nctId":"NCT05686980","phase":"PHASE1","title":"A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-01-17","conditions":"Healthy Volunteers","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ABBV-552","genericName":"ABBV-552","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABBV-552 is a small molecule inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1). Used for Moderate to severe multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}